Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s369. https://doi.org/10.25251/skin.8.supp.369